Prosecution Insights
Last updated: October 26, 2026
Application No. 18/818,762

COIN-SIZED, FULLY INTEGRATED AND MINIMALLY INVASIVE CONTINUOUS GLUCOSE MONITORING SYSTEM (CGMs) BASED ON ORGANIC ELECTROCHEMICAL TRANSISTORS

Non-Final OA §112
Filed
Aug 29, 2024
Priority
Jan 04, 2024 — provisional 63/617,436
Examiner
SHAH, JAY B
Art Unit
Tech Center
Assignee
The University of Hong Kong
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
64%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
237 granted / 406 resolved
-1.6% vs TC avg
Moderate +6% lift
Without
With
+6.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
39 currently pending
Career history
452
Total Applications
across all art units

Statute-Specific Performance

§101
18.1%
-21.9% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
12.8%
-27.2% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 406 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 (rest by dependency) recites “minimal intrusiveness”. The scope of this limitation is unclear as the term “minimal intrusiveness” is open to interpretation. Claim 1 (rest by dependency) recites “miniaturized readout”. The scope of this limitation is unclear as the term “miniaturized” is open to interpretation. Claim 6 recites “the signal to noise ratio”. There is insufficient antecedent basis for this limitation. It is also unclear what the SNR refers to in this case. Claim 7 recites “the gate voltage”. There is insufficient antecedent basis for this limitation. It is also unclear what the gate voltage refers to in this case. Claim 8 recites “the gate voltage”. There is insufficient antecedent basis for this limitation. It is also unclear what the gate voltage refers to in this case. Claim 8 recites “the transconductance”. There is insufficient antecedent basis for this limitation. It is also unclear what the transconductance refers to in this case. Claim 8 recites “the anti-noise ability”. There is insufficient antecedent basis for this limitation. It is also unclear what the anti-noise ability refers to in this case. Claim 8 recites “the linear range of detection”. There is insufficient antecedent basis for this limitation. It is also unclear what the linear range of detection refers to in this case. Claim 9 recites “the transconductance curves”. There is insufficient antecedent basis for this limitation. It is also unclear what the transconductance curves refers to in this case. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 4 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 4 merely contains limitations related to what the system may be capable of, but fails to structurally limit the claim. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claim 1-9 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: The closest prior arts of record (Bai et al – cited below; Jina et al; Chua et al; Zhang et al; - all cited by Applicant) while teaching separate components of the claimed invention fail to teach the combination of an OECT based glucose sensor with a hollow microneedle patch with a 3D printed resin encapsulation case with evaporated metal coating. None of the prior art considered, alone or in combination, teaches that particular feature combined with the other limitations of the claim. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US-20250000392-A1 US-20240374169-A1 US-20230363713-A1 US-20210290829-A1 Bai et al. Coin- sized, fully integrated, and minimally invasive continuous glucose monitoring system based on organic electrochemical transistors; Sci. Adv. 10, eadl1856 (2024) 19 April 2024 Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAY B SHAH whose telephone number is (571)272-0686. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at 571-272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JAY SHAH Primary Examiner Art Unit 3791 /JAY B SHAH/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Aug 29, 2024
Application Filed
Oct 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12755738
Method of Contextual Speech Decoding From the Brain
1y 6m to grant Granted Oct 06, 2026
Patent 12745950
HYPERHIDROSIS DIAGNOSTIC DEVICE AND METHOD
2y 8m to grant Granted Sep 29, 2026
Patent 12740741
CONDUCTIVE HYDROGEL PAPER-BASED DEVICE FOR SYNCHRONOUSLY MONITORING PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS
2y 7m to grant Granted Sep 22, 2026
Patent 12738275
Method of Contextual Speech Decoding from the Brain
4y 8m to grant Granted Sep 15, 2026
Patent 12721543
APPARATUS AND METHODS FOR VIRAL AND BACTERIAL BREATH COLLECTION
3y 9m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
64%
With Interview (+6.0%)
3y 4m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 406 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month